BLACK FRIDAY

ADVFN

Celebrating 25 years Est 1999-2024

Save up to 60%* for Ultimate Trader

1 year 40%, 2 years 50% and *3 years 60%

*Across 3 years $3395.52 only $1358.21

ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,969.34
      0.35%
      US Tech 100
      20,266.40
      0.33%
      Dow Jones
      44,296.51
      0.97%
      Brent Oil
      74.65
      0.00%
      Bitcoin
      97,372.96
      -0.43%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. AMEX

      6. Channel Therapeutics Corporation (CHRO) Quote

      Channel Therapeutics Corporation

      Channel Therapeutics Corporation (CHRO)

      AMEX
      0.66
      0.0288
      (4.56%)
      Closed November 24 4:00PM
      Delayed by 15 minutes
      0.6251
      -0.0349
      (-5.29%)
      After Hours: 6:43PM
      Delayed by 15 minutes

      Empower your portfolio: Real-time discussions and actionable trading ideas.

      Premium

      Key stats and details

      Current Price
      0.6251
      Bid
      -
      Ask
      -
      Volume
      85,435
      0.5966 Day's Range 0.6625
      0.45 52 Week Range 6.00
      Market Cap
      3.768M
      Previous Close
      0.6312
      Open
      0.619
      Last Trade
      100
      @
      0.66
      Last Trade Time
      Financial Volume
      $ 54,559
      VWAP
      0.6386
      Average Volume (3m)
      136,208
      Shares Outstanding
      6,028,011
      Dividend Yield
      -
      PE Ratio
      -0.54
      Earnings Per Share (EPS)
      -1.22
      Revenue
      -
      Net Profit
      -7.38M

      About Channel Therapeutics Corporation

      Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. I... Chromocell Therapeutics Corporation, a clinical-stage biotech company, focuses on the discovery, development, and commercialization of new therapeutics to alleviate pain. The company intends to selectively target the sodium ion-channel known as NaV1.7, as well as other receptors in the NaV family. Its lead compound comprises CC8464, which is in Phase 2a clinical trials for use in the treatment of erythromelalgia, as well as other fields of neuropathic pain. Chromocell Therapeutics Corporation was founded in 2002 and is based in Freehold, New Jersey. Show more

      Sector
      Biological Pds,ex Diagnstics
      Industry
      Biological Pds,ex Diagnstics
      Website
      chromocell.com
      Headquarters
      Wilmington, Delaware, USA
      Founded
      -
      Channel Therapeutics Corporation is listed in the Biological Pds,ex Diagnstics sector of the American Stock Exchange with ticker CHRO. The last closing price for Channel Therapeutics was $0.63. Over the last year, Channel Therapeutics shares have traded in a share price range of $ 0.45 to $ 6.00.

      Channel Therapeutics currently has 6,028,011 shares outstanding. The market capitalization of Channel Therapeutics is $3.80 million. Channel Therapeutics has a price to earnings ratio (PE ratio) of -0.54.

      Ask ADVFN Intelligence (AI)

      CHRO Latest News

      More News

      Chromocell Announces Amendment to Stock Repurchase Plan

      FREEHOLD, N.J., Oct. 24, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...

      October 24 2024
      GlobeNewswire Inc.

      Chromocell to Participate in the Virtual Investor Lunch Break Series

      FREEHOLD, N.J., July 15, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...

      July 15 2024
      GlobeNewswire Inc.

      Form 4 - Statement of changes in beneficial ownership of securities

      June 18 2024
      Edgar (US Regulatory)

      Form 424B3 - Prospectus [Rule 424(b)(3)]

      May 15 2024
      Edgar (US Regulatory)

      Form 10-Q - Quarterly report [Sections 13 or 15(d)]

      May 15 2024
      Edgar (US Regulatory)

      Chromocell To Present at Alliance Global Partner’s Healthcare Company Showcase on Tuesday, May 21, 2024

      FREEHOLD, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...

      May 13 2024
      GlobeNewswire Inc.

      Chromocell Issues Letter to Stockholders from Chief Executive Officer

      FREEHOLD, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corporation (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...

      April 09 2024
      GlobeNewswire Inc.

      Chromocell Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler

      FREEHOLD, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...

      March 21 2024
      GlobeNewswire Inc.

      Chromocell Names Frank Knuettel as Chief Executive Officer, Removing Interim Status Held Since July 2023

      FREEHOLD, N.J., March 18, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain...

      March 18 2024
      GlobeNewswire Inc.

      Chromocell to Present at Sidoti Virtual Investor Conference March 13-14

      AUSTIN, Texas, March 11, 2024 (GLOBE NEWSWIRE) -- Chromocell Therapeutics Corp. (“Chromocell”, or the “Company”), (NYSE American: CHRO), a pioneer in the development of non-opioid pain treatment...

      March 11 2024
      GlobeNewswire Inc.
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1-0.0059-0.9350237717910.6310.690.45360550.60358874CS
      4-0.0959-13.30097087380.7210.760.45534320.6359142CS
      12-0.2649-29.76404494380.891.110.451362080.79670752CS
      26-1.0749-63.22941176471.71.80.45766570.85183901CS
      52-5.3749-89.5816666667660.45598041.16430877CS
      156-5.3749-89.5816666667660.45598041.16430877CS
      260-5.3749-89.5816666667660.45598041.16430877CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      VINEFresh Vine Wine Inc
      $ 0.8246
      (28.86%)
      		2.1M
      UMACUnusual Machines Inc
      $ 4.76
      (24.93%)
      		461.87k
      CATXPerspective Therapeutics Inc
      $ 3.495
      (16.50%)
      		10.43M
      TPETTrio Petroleum Corp
      $ 1.35
      (15.38%)
      		909.2k
      MSTUT Rex 2X Long MSTR Daily Target ETF
      $ 209.77
      (13.69%)
      		10.42M
      LCTXLineage Cell Therapeutics Inc
      $ 0.50325
      (-16.13%)
      		15.45M
      MSTZT Rex 2X Inverse MSTR Daily Target ETF
      $ 0.9467
      (-11.52%)
      		795.18M
      FOXOFOXO Technologies Inc
      $ 0.53
      (-11.50%)
      		2.24M
      BOILProShares Ultra Bloomberg Natural Gas New
      $ 45.555
      (-11.34%)
      		4.07M
      DDCDDC Enterprise Limited
      $ 0.1825
      (-8.75%)
      		615.59k
      MSTZT Rex 2X Inverse MSTR Daily Target ETF
      $ 0.9467
      (-11.52%)
      		795.18M
      NVDQT Rex 2X Inverse NVIDIA Daily Target ETF
      $ 3.22
      (6.62%)
      		56.33M
      FXIiShares China Large Cap
      $ 29.69
      (-2.17%)
      		53.99M
      SOXLDirexion Daily Semiconductor Bull 3X Shares
      $ 28.49
      (0.00%)
      		50.44M
      SPXSDirexion Daily S&P 500 Bear 3X Shares New
      $ 6.035
      (-0.74%)
      		49.69M

      Discussion

      View Full Feed
      capgain capgain 8 minutes ago
      Good morning all. I can't believe that show is still on the air.
      HGilS HGilS 9 minutes ago
      Not interesting and wrong assumptions

      When I asked the question about our ability to buy api for the coming launches , vyvanse was on the table. His answer was the reason we want to have launches every 6 to eight weeks was so we get paid for the first launches when the new launches ha
      ELTP
      SkeBallLarry SkeBallLarry 9 minutes ago
      " That's a Classic, Shorenuff " .. !!
      MiamiGent MiamiGent 10 minutes ago
      Thanks for sharing this BDEZ. So, he is die in the wool pro-liberty, anti-socialism. Great. What we need on our team.

      Funny, I remember his commercials and distinctive voice but nothing about his content.
      Maybe cause those dam commercials are so long!

      I totally
      dennisdave dennisdave 11 minutes ago
      since NWBO's DCVAX is already in a joint trial with Meck and interim results suggest an incredible OS most likely is Merck.

      Or, a dark horse, but very logical, CSF1R inhibitor, one of which is:
      Daichii Sankyo
      I don't think thats logical at all since adding CSF1R inhi
      NWBO
      StayHumble StayHumble 12 minutes ago
      w0w Xcellent✅Kramers 100% Involved✅BillionsNakedSH0rt ???

      It explains the situation about shorting and naked shorting perfectly!

      Again, this is a MUST WATCH video for anyone who believes in $DBMM (naked or otherwise)!

      I'd love to hear
      DBMM
      JOoa0ky JOoa0ky 13 minutes ago
      At least Bradford's is fuuuuureeeeee.
      FNMA
      dennisdave dennisdave 13 minutes ago
      delete
      NWBO
      ksquared ksquared 14 minutes ago
      Freshman enrollment is down at US colleges — and after the past few years, it’s no wonder
      By Naomi Schaefer Riley and James Piereson Published Nov. 23, 2024, 10:00 a.m. ET

      Higher education is taking a hit.

      According to new data from the National Student Clearing
      SHORENUFFSTUFF SHORENUFFSTUFF 14 minutes ago
      A Southern small-town prosecuting attorney...

      called his first witness, a grandmotherly, elderly woman to the stand. He approached her and asked, 'Mrs. Jones, do you know me?' She responded, 'Why, yes, I do know you, Mr. Williams. I've known you since you were a boy, and frankly, yo
      brooklyn13 brooklyn13 15 minutes ago
      Well congratulations, guys. Your constant referencing of Biden as Genocide Joe and insistence that America is aiding in a genocide helped people to rationalize a choice to sit out the election or vote for Stein, or even,Trump. Which helped enable the Trump victory.

      And now with note
      oldstocks oldstocks 15 minutes ago
      Dell Digital Health

      https://www.dell.com/en-us/lp/industry-healthcare-it

      Possibilities are there
      AFFU
      Rodney5 Rodney5 15 minutes ago
      You can’t pay me $5 to read his stuff.
      FNMA
      TRAPPER JIM TRAPPER JIM 15 minutes ago
      Are we there yet 
      RSPI
      NickyCapone NickyCapone 17 minutes ago
      Go apes!

      The greatest transfer of wealth in the world history is taking place with AMC hosted by the Apes!

      Sweet Sweet JUSTICE is marching in carrying all Apes & supporters to Financial Victory!
      Amin
      AMC
      Rodney5 Rodney5 18 minutes ago
      Kim, “ FHFA needs to be cut ASAP, as it is wasting $150,000,000 payroll per year to put FnF in the conservatorship.”.

      Can we document verified payroll numbers with number of employees? Elon Musk &Co should be notified. Thanks
      FNMA
      TRAPPER JIM TRAPPER JIM 18 minutes ago
      Got three walls painted in the garage. I have almost all the shelving done. The storage unit is empty. And the Buckeyes beat the undefeated Indiana Hoosiers. We play the big rivalry game against Michigan next weekend 
      chrismiss_everyday chrismiss_everyday 19 minutes ago
      ⏳Exciting possibilities. 📈 s1R
      Bullish about near-term ‘cattle’-ysts.
      A week of giving thanks for small molecule development and mitochondrial homeostasis,
      AVXL
      GARYM1 GARYM1 20 minutes ago
      Your optimistic view is encouraging
      SEV
      sab63090 sab63090 21 minutes ago
      Tom:
      Makes sense for those who are not willing to anticipate a move up to wait. I think we have either a 3rd Wave continuing up or a "hook rally", I.e. a print high under the spike high; my bet is a push up from here!

      ....you are certainly correct in your analysis of the last
      AVXL
      MrLourdes MrLourdes 23 minutes ago
      The Prevail Act: A Potential Game-Changer for Netlist Inc. in its Fight Against Samsung, Micron, and Google
      Please Feel Free To Share Article
      https://www.linkedin.com/pulse/prevailing-act-potential-game-changer-netlist-inc-its-gary-wallach-2peve/

      NLST
      StayHumble StayHumble 23 minutes ago
      No R/s✅$5M BUYBACK✅Dividend✅$HCWC has a 4-point plan✅

      -A buyback of up to $5M of $HCMC common stock.

      -A spinoff of certain HCMC assets into a new publicly traded company

      -A stock dividend to $HCMC shareholders of the stock in N
      HCMC HCWC
      Hulk Hogan is God Hulk Hogan is God 25 minutes ago
      So they identified a weakness by realizing nobody over there knows how to file with the SEC?

      Muhahahaha!!!!  Are you kidding us?!?  Talk about an admission of incompetence!

      No wonder this thing is failing
      WRAP
      jimr1717 jimr1717 25 minutes ago
      ATMH DD Updated 🏆️ >>

      Read the 30,000,000 offering and the registration of 12,000,000 plus restricted shares to be sold.
      The friends and family names are also listed…..

      https://www.nasdaq.com/market-activity/stocks/atmh/sec-filings

      T
      ATMH
      StayHumble StayHumble 25 minutes ago
      ✅Lots of Historical XPERT interest in $HIRU✅✅✅https://ih.advfn.com/stock-market/USOTC/hiru-pk-HIRU/historical
      HIRU

      Your Recent History

      AMEX
      CHRO
      Channel Therapeutics
      Delayed Upgrade Clock